Information Provided By:
Fly News Breaks for April 24, 2018
Apr 24, 2018 | 07:13 EDT
Cantor Fitzgerald analyst William Tanner lowered his price target for Prothena (PRTA) to $14 to reflect NEOD001 being discontinued but maintains an Overweight rating on the shares. While it is possible that additional selling pressure could ensue, previously uninvolved investors may appreciate the buying opportunity following yesterday's selloff, given Prothena's "important" collaborations with Roche (RHHBY) and Celgene (CELG), Tanner tells investors in a research note.
News For PRTA From the Last 2 Days
There are no results for your query PRTA